The versatility of HMN-384 has sparked interest in its potential applications across various therapeutic areas. Some of the most promising indications include:
Unveiling HMN-384: The Future of Innovation and Technology HMN-384
The dysregulation of cyclin-dependent kinases (CDKs) is a hallmark of tumorigenesis, driving uncontrolled proliferation through the evasion of cell cycle checkpoints and aberrant transcriptional programs. The clinical approval of CDK4/6 inhibitors (e.g., palbociclib, ribociclib) has revolutionized the treatment of hormone receptor-positive breast cancer. However, a significant subset of patients, particularly those with Triple-Negative Breast Cancer (TNBC), derive limited benefit from CDK4/6 inhibition due to the loss of the retinoblastoma (Rb) pathway or cyclin D1 overexpression. The versatility of HMN-384 has sparked interest in